Literature DB >> 23545371

Influence of "GERD" label on parents' decision to medicate infants.

Laura D Scherer1, Brian J Zikmund-Fisher, Angela Fagerlin, Beth A Tarini.   

Abstract

BACKGROUND: The factors that drive overtreatment of gastroesophageal reflux disease (GERD) are not well understood, but it has been proposed that the use of the "GERD" disease label could perpetuate use of medication in otherwise healthy infants.
METHODS: To determine if use of the disease label GERD influences parents' perceived need to medicate an infant, we surveyed parents in a general pediatric clinic. Parents were given a hypothetical clinical scenario describing an infant who cries and spits up excessively but is otherwise healthy. Using a 2 × 2 factorial design, parents were randomized to receive a scenario in which the doctor either gave a diagnosis of GERD or did not provide a disease label; additionally, half of parents were told that existing medications are probably ineffective, whereas the rest were not given any effectiveness information. We measured parent interest in medication, perception of illness severity, and appreciation of medication offer.
RESULTS: Parents who received a GERD diagnosis were interested in medicating their infant, even when they were told that the medications are likely ineffective. However, parents not given a disease label were interested in medication only when medication effectiveness was not discussed (and hence likely assumed).
CONCLUSIONS: Labeling an otherwise healthy infant as having a "disease" increased parents' interest in medicating their infant when they were told that medications are ineffective. These findings suggest that use of disease labels may promote overtreatment by causing people to believe that ineffective medications are both useful and necessary.

Entities:  

Keywords:  GERD; Gastroesophageal reflux disease; disease labels; overtreatment

Mesh:

Substances:

Year:  2013        PMID: 23545371      PMCID: PMC3639462          DOI: 10.1542/peds.2012-3070

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it.

Authors:  Eric Hassall
Journal:  J Pediatr       Date:  2011-10-22       Impact factor: 4.406

2.  Choosing wisely: helping physicians and patients make smart decisions about their care.

Authors:  Christine K Cassel; James A Guest
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

3.  Pantoprazole for symptoms of infant GERD: the emperor has no clothes!

Authors:  Susan R Orenstein; Eric Hassall
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-10       Impact factor: 2.839

Review 4.  Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.

Authors:  Rachel J van der Pol; Marije J Smits; Michiel P van Wijk; Taher I Omari; Merit M Tabbers; Marc A Benninga
Journal:  Pediatrics       Date:  2011-04-04       Impact factor: 7.124

Review 5.  Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Authors:  Tanner W Higginbotham
Journal:  Ann Pharmacother       Date:  2010-02-02       Impact factor: 3.154

6.  Does labelling and treatment for hypertension increase illness behaviour?

Authors:  C van Weel
Journal:  Fam Pract       Date:  1985-09       Impact factor: 2.267

7.  Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.

Authors:  Susan R Orenstein; Eric Hassall; Wanda Furmaga-Jablonska; Stuart Atkinson; Marsha Raanan
Journal:  J Pediatr       Date:  2008-12-03       Impact factor: 4.406

8.  Increased absenteeism from work after detection and labeling of hypertensive patients.

Authors:  R B Haynes; D L Sackett; D W Taylor; E S Gibson; A L Johnson
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

9.  Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.

Authors:  S P Nelson; S Kothari; E Q Wu; N Beaulieu; J M McHale; O H Dabbous
Journal:  J Med Econ       Date:  2009       Impact factor: 2.448

10.  Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN).

Authors:  Yvan Vandenplas; Colin D Rudolph; Carlo Di Lorenzo; Eric Hassall; Gregory Liptak; Lynnette Mazur; Judith Sondheimer; Annamaria Staiano; Michael Thomson; Gigi Veereman-Wauters; Tobias G Wenzl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-10       Impact factor: 2.839

View more
  16 in total

1.  The Impact of the American Academy of Pediatrics Brief Resolved Unexplained Event Guidelines on Gastrointestinal Testing and Prescribing Practices.

Authors:  Daniel R Duncan; Amanda S Growdon; Enju Liu; Kara Larson; Madeline Gonzalez; Kerri Norris; Rachel L Rosen
Journal:  J Pediatr       Date:  2019-05-15       Impact factor: 4.406

Review 2.  From evidence to best practice in laboratory medicine.

Authors:  A Rita Horvath
Journal:  Clin Biochem Rev       Date:  2013-08

3.  The frequency of and factors affecting functional gastrointestinal disorders in infants that presented to tertiary care hospitals.

Authors:  Omer Faruk Beser; Fugen Cullu Cokugras; Guzide Dogan; Ozlem Akgun; Murat Elevli; Pinar Yilmazbas; Meric Ocal; Nevzat Aykut Bayrak; Rabia Gonul Sezer Yamanel; Abdulkadir Bozaykut; Coşkun Celtik; Esra Polat; Nelgin Gerenli; Serdar Bozlak; Hasret Ayyildiz Civan; Neslihan Ozkul Saglam; Sadik Sami Hatipoglu; Gamze Özgürhan; Eda Sunnetci Silistre; Burcu Solmaz; Gunsel Kutluk; Hamide Sevinc Genc; Hasan Onal; Ayse Merve Usta; Nafiye Urganci; Ayse Sahin; Sebahat Cam; Sema Yildirim; Asilay Yildirim; Yvan Vandenplas
Journal:  Eur J Pediatr       Date:  2021-04-03       Impact factor: 3.183

4.  Characterizing the Language Used to Discuss Death in Family Meetings for Critically Ill Infants.

Authors:  Margaret H Barlet; Mary C Barks; Peter A Ubel; J Kelly Davis; Kathryn I Pollak; Erica C Kaye; Kevin P Weinfurt; Monica E Lemmon
Journal:  JAMA Netw Open       Date:  2022-10-03

5.  "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication.

Authors:  Ilona Fridman; Peter A Ubel; Jennifer Blumenthal-Barby; Cameron V England; Judith S Currier; Nir Eyal; Kenneth A Freedberg; Scott D Halpern; Colleen F Kelley; Daniel R Kuritzkes; Catherine N Le; Jeffrey L Lennox; Kathryn I Pollak; Brian J Zikmund-Fisher; Karen A Scherr
Journal:  AIDS Behav       Date:  2020-07

Review 6.  Words do matter: a systematic review on how different terminology for the same condition influences management preferences.

Authors:  Brooke Nickel; Alexandra Barratt; Tessa Copp; Ray Moynihan; Kirsten McCaffery
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

7.  The benefits and harms of receiving a polycystic ovary syndrome diagnosis: a qualitative study of women's experiences.

Authors:  T Copp; J Hersch; D M Muscat; K J McCaffery; J Doust; A Dokras; B W Mol; J Jansen
Journal:  Hum Reprod Open       Date:  2019-10-31

8.  Effects of Influenza Strain Label on Worry and Behavioral Intentions.

Authors:  Aaron M Scherer; Megan Knaus; Brian J Zikmund-Fisher; Enny Das; Angela Fagerlin
Journal:  Emerg Infect Dis       Date:  2017-08       Impact factor: 6.883

9.  The enigma of gastroesophageal reflux disease among convalescing infants in the NICU: It is time to rethink.

Authors:  Eman F Badran; Sudarshan Jadcherla
Journal:  Int J Pediatr Adolesc Med       Date:  2020-03-05

10.  A randomised on-line survey exploring how health condition labels affect behavioural intentions.

Authors:  Rae Thomas; Mark T Spence; Rajat Roy; Elaine Beller
Journal:  PLoS One       Date:  2020-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.